Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Squibb : Invests in Europe with New Cell Therapy Manufacturing Site Planned in the Netherlands

04/22/2021 | 07:08am EDT

Bristol Myers Squibb announced the company has selected Leiden, Netherlands to house a new cell therapy manufacturing site in Europe, leveraging the growing life sciences region near Amsterdam and convenient access to transportation for shipping patient cells.

As part of Bristol Myers Squibb's continuing commitment to patients with aggressive hematological cancers and its growing cell therapy franchise, the company is making this significant new investment to expand global manufacturing capacity and bring treatments to patients faster. Leiden will be the company's fifth state-of-the-art cell therapy manufacturing facility and first in Europe, in addition to major contract manufacturing partnerships globally.

'A key element of BMS' commitment to cell therapy is our continuous investment in advanced manufacturing capabilities, from the expansion of our global network and capacity to treat patients to reduced turn around time and optimized costs,' said Ann Lee, Ph.D., Senior Vice President, Cell Therapy Development & Operations, Bristol Myers Squibb. 'We continue to grow our presence in Europe and the Netherlands, which offers an innovative life sciences hub and world class industry talent, and we look forward to hiring several hundred talented people over the coming years to join our global team and participate in our cell therapy journey.'

The European facility will be commercially focused with capabilities for multi-product cell therapy manufacturing and the ability to scale up capacity. It will leverage innovative technologies,the latest manufacturing equipment and advanced digital systems to deliver these critical cell therapies to patients.

Planning for site design and development is underway, with construction slated to begin later this year.

Related Content:

Media Inquiries:
[email protected]

Tara Morgan
[email protected]

Investors:
Tim Power
609-252-7509
[email protected]

Disclaimer

Bristol-Myers Squibb Company published this content on 22 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 April 2021 11:07:03 UTC.


© Publicnow 2021
All news about BRISTOL-MYERS SQUIBB COMPANY
05/07INSIDER TRENDS : 90-Day Insider Buying Trend at Bristol-Myers Squibb Interrupted..
MT
05/07INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Bristol-Myer..
MT
05/07EVOTEC  : launches 'beLAB1407' to accelerate translational research from the UK'..
AQ
05/06BRISTOL MYERS SQUIBB CO  : Submission of Matters to a Vote of Security Holders, ..
AQ
05/06GLAXOSMITHKLINE  : GSK Appoints Charles Bancroft As Member Of Nominations & Corp..
RE
05/06DARWINHEALTH  : Announces a Research Collaboration with Bristol Myers Squibb for..
PR
05/05BRISTOL MYERS SQUIBB  : to Take Part in the 2021 Bank of America Securities Heal..
BU
05/04BRISTOL MYERS SQUIBB CO  : Change in Directors or Principal Officers, Amendments..
AQ
05/03BRISTOL MYERS SQUIBB  : Presents New Clinical and Real-World Data on Mavacamten ..
BU
04/30BRISTOL MYERS SQUIBB  : Application for Opdivo Accepted by FDA for Priority Revi..
MT
More news
Financials (USD)
Sales 2021 46 094 M - -
Net income 2021 7 190 M - -
Net Debt 2021 26 819 M - -
P/E ratio 2021 20,2x
Yield 2021 3,02%
Capitalization 144 B 144 B -
EV / Sales 2021 3,70x
EV / Sales 2022 3,35x
Nbr of Employees 30 250
Free-Float 76,3%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 75,46 $
Last Close Price 64,44 $
Spread / Highest target 39,7%
Spread / Average Target 17,1%
Spread / Lowest Target -3,79%
EPS Revisions
Managers and Directors
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY3.89%143 884
JOHNSON & JOHNSON7.07%443 727
ROCHE HOLDING AG-1.88%289 958
PFIZER, INC.7.53%220 784
ABBVIE INC.8.03%204 279
MERCK & CO., INC.-4.14%198 539